Following the fate of the failing b-cell: New insights from first-phase insulin responses

Diabetes

Volumn 62, Issue 12, 2013, Pages 3990-3992

  Williams, Alistair J K ^a   Long, Anna E ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUCOSE; INSULIN;

DIABETES MELLITUS; HUMAN; INSULIN RESPONSE; INTRAVENOUS GLUCOSE TOLERANCE TEST; NOTE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; BLOOD; FEMALE; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MALE; PHYSIOLOGY;

DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; PREDIABETIC STATE;

EID: 84891812271     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1314     Document Type: Note

References (20)

1. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836
2. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 2007;7:988-994
3. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309:2473-2479
4. Di Gialleonardo V, de Vries EF, Di Girolamo M, Quintero AM, Dierckx RA, Signore A. Imaging of b-cell mass and insulitis in insulin-dependent (type 1) diabetes mellitus. Endocr Rev 2012;33:892-919
5. Xu P, Wu Y, Zhu Y, et al.; Diabetes Prevention Trial-Type 1 (DPT-1) Study Group. Prognostic performance of metabolic indexes in predicting onset of type 1 diabetes. Diabetes Care 2010;33:2508-2513
6. Meier JJ, Menge BA, Breuer TG, et al. Functional assessment of pancreatic beta-cell area in humans. Diabetes 2009;58:1595-1603
7. Robertson RP. Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient? Diabetes 2007;56:2420-2424
8. Bingley PJ, Matthews DR, Williams AJ, Bottazzo GF, Gale EA. Loss of regular oscillatory insulin secretion in islet cell antibody positive nondiabetic subjects. Diabetologia 1992;35:32-38
9. Truyen I, De Pauw P, Jørgensen PN, et al.; Belgian Diabetes Registry. Proinsulin levels and the proinsulin:C-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia 2005;48: 2322-2329
10. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixedmeal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971
11. Bingley PJ, Colman P, Eisenbarth GS, et al. Standardization of IVGTT to predict IDDM. Diabetes Care 1992;15:1313-1316
12. Sosenko JM, Skyler JS, Beam CA, et al.; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 participants. Diabetes 2013;62:4179-4183
13. Bleich D, Jackson RA, Soeldner JS, Eisenbarth GS. Analysis of metabolic progression to type I diabetes in ICA+ relatives of patients with type I diabetes. Diabetes Care 1990;13:111-118
14. Chaillous L, Rohmer V, Maugendre D, et al. Differential beta-cell response to glucose, glucagon, and arginine during progression to type I (insulin-dependent) diabetes mellitus. Metabolism 1996;45: 306-314
15. Sosenko JM, Skyler JS, Herold KC, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-Type. Diabetes 2012;61:1331-1337
16. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type. Diabetes Care 2005;28:1068-1076
17. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004;47:1661-1667
18. Bingley PJ, Mahon JL, Gale EA; European Nicotinamide Diabetes Intervention Trial Group. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008;31:146-150
19. Smith CP, Tarn AC, Thomas JM, et al. Between and within subject variation of the first phase insulin response to intravenous glucose. Diabetologia 1988;31:123-125
20. Weir GC, Bonner-Weir S. Islet b cell mass in diabetes and how it relates to function, birth, and death. Ann N Y Acad Sci 2013;1281:92-105